View Older Stories View More Recent Stories

Aug 11, 2022 06:01AM Form 13F-NT Atlas Venture Fund VIII, For: Jun 30
Aug 10, 2022 07:30AM Gemini Therapeutics (GMTX) and Disc Medicine Announce Merger Agreement
Aug 10, 2022 07:30AM Gemini Therapeutics and Disc Medicine Announce Merger Agreement
Aug 3, 2022 07:00AM AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
Jul 20, 2022 04:23PM Form SC 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
Jul 20, 2022 07:00AM Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity
Jul 19, 2022 05:29PM Form 4 Aerovate Therapeutics, For: Jul 15 Filed by: Atlas Venture Fund XII, L.P.
Jul 7, 2022 08:00AM Kinaset Therapeutics Appoints Christopher O’Brien, MD, PhD, FCCP, as Chief Medical Officer
Jul 6, 2022 04:42PM Form 4 Day One Biopharmaceutica For: Jul 01 Filed by: Atlas Venture Opportunity Fund I, L.P.
Jun 22, 2022 05:10PM Form 4 Day One Biopharmaceutica For: Jun 17 Filed by: Atlas Venture Associates XI, L.P.
Jun 3, 2022 08:00AM Replimune Announces the Departure of Jason Rhodes from its Board of Directors
May 19, 2022 06:30AM Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines
May 17, 2022 06:45AM Remix Therapeutics Closes $70 Million Series B Financing
May 16, 2022 04:02PM Form 13F-HR Atlas Venture Life Scien For: Mar 31
May 16, 2022 03:54PM Form 13F-HR Atlas Venture Life Scien For: Dec 31
May 12, 2022 01:48PM Form 13F-NT Atlas Venture Fund VIII, For: Mar 31
May 12, 2022 01:46PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 12, 2022 01:44PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 12, 2022 01:38PM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 12, 2022 01:37PM Form 13F-HR Atlas Venture Associates For: Mar 31
May 5, 2022 04:06PM Form SC 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
May 5, 2022 04:02PM Form SC 13D/A Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Apr 26, 2022 07:00AM Vedere Bio II Appoints Accomplished Clinician and Researcher Anna-Maria Demetriades as Chief Medical Officer
Apr 25, 2022 08:04AM Perspective Group Announcing the Formation of an Advisory Board
Apr 19, 2022 08:00AM Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis
Apr 14, 2022 06:30AM Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
Apr 12, 2022 07:00AM Vedere Bio II Announces Appointment of Industry Veteran Gina Consylman as Chief Financial Officer
Apr 11, 2022 04:01AM Highview Power Names Rupert Pearce Chief Executive Officer
Apr 6, 2022 09:00AM  TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues
Apr 4, 2022 05:13PM Form 4 Aerovate Therapeutics, For: Apr 01 Filed by: Atlas Venture Fund XII, L.P.
Apr 4, 2022 08:00AM Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors
Mar 3, 2022 03:09PM Form D Atlas Venture Fund XIII,
Mar 3, 2022 07:00AM Atlas Venture Announces $450 Million Fund XIII
Feb 16, 2022 06:00AM Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation
Feb 14, 2022 06:18AM Form SC 13G/A F-star Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Feb 11, 2022 05:40PM Form SC 13G/A Akero Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 11, 2022 05:28PM Form SC 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 11, 2022 05:23PM Form SC 13G Day One Biopharmaceutica Filed by: Atlas Venture Fund XI, L.P.
Feb 11, 2022 05:20PM Form SC 13D Ikena Oncology, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 11, 2022 05:18PM Form SC 13G/A Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 11, 2022 05:14PM Form SC 13G/A Generation Bio Co. Filed by: Atlas Venture Fund X, L.P.
Feb 10, 2022 07:00AM Arkuda Therapeutics Raises $64 Million Series B Financing to Advance Pipeline of Programs Targeting Lysosomal Biology to Treat Neurodegenerative Diseases
Feb 8, 2022 07:00AM Vedere Bio II Appoints Martina Schinke, Ph.D., as Vice President, Program Leader
Feb 7, 2022 03:39PM Form SC 13G INTEGRAL AD SCIENCE HOLD Filed by: Atlas Venture Fund VIII, L.P.
Jan 27, 2022 10:53AM Form 13F-HR Atlas Venture Advisors, For: Dec 31
Jan 27, 2022 06:08AM Form 13F-NT Atlas Venture Fund VIII, For: Dec 31
Jan 27, 2022 06:05AM Form 13F-NT Atlas Venture Associates For: Dec 31
Jan 27, 2022 06:05AM Form 13F-NT Atlas Venture Associates For: Dec 31
Jan 27, 2022 06:04AM Form 13F-HR Atlas Venture Associates For: Dec 31
Jan 25, 2022 11:33AM Form SC 13G/A Cogent Biosciences, Inc. Filed by: Atlas Venture Fund IX, L.P.
View More Recent Stories View Older Stories